Taro Kishi

List of Publications by Citations

Source: https://exaly.com/author-pdf/6815460/taro-kishi-publications-by-citations.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

154 papers	3,154 citations	32 h-index	48 g-index
159 ext. papers	3,671 ext. citations	4.7 avg, IF	5.44 L-index

#	Paper	IF	Citations
154	Genome-wide association study of schizophrenia in a Japanese population. *Biological Psychiatry*, **2011**, 69, 472-8	7.9	145
153	Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. *PLoS ONE* , **2015**, 10, e0123289	3.7	125
152	Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis. *Journal of Alzheimer's Disease*, **2017**, 60, 401-425	4.3	108
151	Meta-analysis of association between genetic variants in COMT and schizophrenia: an update. *Schizophrenia Research*, **2009**, 110, 140-8	3.6	103
150	Copy number variation in schizophrenia in the Japanese population. *Biological Psychiatry*, **2010**, 67, 283-6	7.9	95
149	Brain-Derived Neurotrophic Factor and Major Depressive Disorder: Evidence from Meta-Analyses. *Frontiers in Psychiatry*, **2017**, 8, 308	5	94
148	SIRT1 gene is associated with major depressive disorder in the Japanese population. *Journal of Affective Disorders*, **2010**, 126, 167-73	6.6	87
147	The serotonin 1A receptor gene confer susceptibility to mood disorders: results from an extended meta-analysis of patients with major depression and bipolar disorder. *European Archives of Psychiatry and Clinical Neuroscience*, **2013**, 263, 105-18	5.1	76
146	Yokukansan in the treatment of behavioral and psychological symptoms of dementia: a systematic review and meta-analysis of randomized controlled trials. *Human Psychopharmacology*, **2013**, 28, 80-6	2.3	71
145	Association study of clock gene (CLOCK) and schizophrenia and mood disorders in the Japanese population. *European Archives of Psychiatry and Clinical Neuroscience*, **2009**, 259, 293-7	5.1	71
144	Antipsychotic medications for the treatment of delirium: a systematic review and meta-analysis of randomised controlled trials. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 767-74	5.5	62
143	Association analysis of nuclear receptor Rev-erb alpha gene (NR1D1) with mood disorders in the Japanese population. *Neuroscience Research*, **2008**, 62, 211-5	2.9	57
142	Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis. *International Journal of Neuropsychopharmacology*, **2014**, 18,	5.8	55
141	Serotonin 1A receptor gene and major depressive disorder: an association study and meta-analysis. *Journal of Human Genetics*, **2009**, 54, 629-33	4.3	53
140	Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. *PLoS ONE*, **2015**, 10, e0136910	3.7	49
139	Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. *Human Psychopharmacology*, **2014**, 29, 483-91	2.3	47
138	NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials. *Journal of Psychiatric Research*, **2013**, 47, 1143-9	5.2	45

137	BDNF is not associated with schizophrenia: data from a Japanese population study and meta-analysis. *Schizophrenia Research*, **2009**, 112, 72-9	3.6	45
136	HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort. *NeuroMolecular Medicine*, **2010**, 12, 237-42	4.6	45
135	Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials. *Journal of Psychiatric Research*, **2013**, 47, 149-54	5.2	44
134	A meta-analysis of inositol for depression and anxiety disorders. *Human Psychopharmacology*, **2014**, 29, 55-63	2.3	42
133	Long-Acting Injectable Antipsychotics for Prevention of Relapse in Bipolar Disorder: A Systematic Review and Meta-Analyses of Randomized Controlled Trials. *International Journal of Neuropsychopharmacology*, **2016**, 19,	5.8	41
132	CLOCK may predict the response to fluvoxamine treatment in Japanese major depressive disorder patients. *NeuroMolecular Medicine*, **2009**, 11, 53-7	4.6	41
131	Prepulse inhibition of the startle response with chronic schizophrenia: a replication study. *Neuroscience Research*, **2009**, 65, 259-62	2.9	41
130	Serotonin 1A receptor gene, schizophrenia and bipolar disorder: an association study and meta-analysis. *Psychiatry Research*, **2011**, 185, 20-6	9.9	39
129	Intramuscular olanzapine for agitated patients: A systematic review and meta-analysis of randomized controlled trials. *Journal of Psychiatric Research*, **2015**, 68, 198-209	5.2	38
128	Relationship between a BDNF gene polymorphism and the brain volume in treatment-naive patients with major depressive disorder: A VBM analysis of brain MRI. *Psychiatry Research - Neuroimaging*, **2015**, 233, 120-4	2.9	37
127	Possible association of prokineticin 2 receptor gene (PROKR2) with mood disorders in the Japanese population. *NeuroMolecular Medicine*, **2009**, 11, 114-22	4.6	34
126	Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials. *European Archives of Psychiatry and Clinical Neuroscience*, **2016**, 266, 439-50	5.1	33
125	The CLOCK gene and mood disorders: a case-control study and meta-analysis. *Chronobiology International*, **2011**, 28, 825-33	3.6	33
124	The efficacy and safety of memantine for the treatment of Alzheimer's disease. *Expert Opinion on Drug Safety*, **2018**, 17, 1053-1061	4.1	33
123	Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis. *European Archives of Psychiatry and Clinical Neuroscience*, **2015**, 265, 259-68	5.1	32
122	Long-acting injectable antipsychotics for the prevention of relapse in patients with recent-onset psychotic disorders: A systematic review and meta-analysis of randomized controlled trials. *Psychiatry Research*, **2016**, 246, 750-755	9.9	30
121	Genetic association analysis of serotonin 2A receptor gene (HTR2A) with bipolar disorder and major depressive disorder in the Japanese population. *Neuroscience Research*, **2009**, 64, 231-4	2.9	30
120	A Meta-Analysis of Memantine for Depression. *Journal of Alzheimer's Disease*, **2017**, 57, 113-121	4.3	29

119	Serotonin 1A receptor gene is associated with Japanese methamphetamine-induced psychosis patients. *Neuropharmacology*, **2010**, 58, 452-6	5.5	29
118	Association analysis of group II metabotropic glutamate receptor genes (GRM2 and GRM3) with mood disorders and fluvoxamine response in a Japanese population. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2009**, 33, 875-9	5.5	29
117	Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis. *Psychopharmacology*, **2017**, 234, 2113-2125	4.7	28
116	The effects of memantine on behavioral disturbances in patients with Alzheimer's disease: a meta-analysis. *Neuropsychiatric Disease and Treatment*, **2017**, 13, 1909-1928	3.1	28
115	Mortality Risk Associated With Long-acting Injectable Antipsychotics: A Systematic Review and Meta-analyses of Randomized Controlled Trials. *Schizophrenia Bulletin*, **2016**, 42, 1438-1445	1.3	28
114	Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis. *International Journal of Neuropsychopharmacology*, **2015**, 19,	5.8	27
113	Association between insertion/deletion polymorphism in angiotensin-converting enzyme gene and acute lung injury/acute respiratory distress syndrome: a meta-analysis. *BMC Medical Genetics*, **2012**, 13, 76	2.1	27
112	Lemborexant vs suvorexant for insomnia: A systematic review and network meta-analysis. *Journal of Psychiatric Research*, **2020**, 128, 68-74	5.2	26
111	Yokukansan in the Treatment of Behavioral and Psychological Symptoms of Dementia: An Updated Meta-Analysis of Randomized Controlled Trials. *Journal of Alzheimer's Disease*, **2016**, 54, 635-43	4.3	26
110	Association analysis of SIGMAR1 with major depressive disorder and SSRI response. *Neuropharmacology*, **2010**, 58, 1168-73	5.5	25
109	Genetic effects on white matter integrity in drug-naive patients with major depressive disorder: a diffusion tensor imaging study of 17 genetic loci associated with depressive symptoms. *Neuropsychiatric Disease and Treatment*, **2019**, 15, 375-383	3.1	24
108	Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review. *NeuroMolecular Medicine*, **2014**, 16, 61-9	4.6	23
107	Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis. *International Journal of Neuropsychopharmacology*, **2013**, 16, 1259-66	5.8	23
106	Genetic association analysis of functional polymorphisms in neuronal nitric oxide synthase 1 gene (NOS1) and mood disorders and fluvoxamine response in major depressive disorder in the Japanese population. *Neuropsychobiology*, **2010**, 61, 57-63	4	23
105	Association analysis of GRM2 and HTR2A with methamphetamine-induced psychosis and schizophrenia in the Japanese population. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2010**, 34, 639-44	5.5	23
104	Investigation of clinical factors influencing cognitive function in Japanese schizophrenia. *Neuroscience Research*, **2010**, 66, 340-4	2.9	21
103	Memantine for Lewy body disorders: systematic review and meta-analysis. *American Journal of Geriatric Psychiatry*, **2015**, 23, 373-383	6.5	20
102	Efficacy and safety of NMDA receptor antagonists augmentation therapy for schizophrenia: an updated meta-analysis of randomized placebo-controlled trials. *Journal of Psychiatric Research*, **2013**, 47, 2018-20	5.2	20

101	Serum proBDNF/BDNF and response to fluvoxamine in drug-naïve first-episode major depressive disorder patients. *Annals of General Psychiatry*, **2014**, 13, 19	3.4	20
100	Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia. *International Journal of Neuropsychopharmacology*, **2014**, 17, 343-54	5.8	19
99	No association between polymorphisms of neuronal oxide synthase 1 gene (NOS1) and schizophrenia in a Japanese population. *NeuroMolecular Medicine*, **2009**, 11, 123-7	4.6	19
98	Folic acid/methylfolate for the treatment of psychopathology in schizophrenia: a systematic review and meta-analysis. *Psychopharmacology*, **2018**, 235, 2303-2314	4.7	19
97	Effect of discontinuation v. maintenance of antipsychotic medication on relapse rates in patients with remitted/stable first-episode psychosis: a meta-analysis. *Psychological Medicine*, **2019**, 49, 772-779	6.9	18
96	A functional polymorphism in estrogen receptor alpha gene is associated with Japanese methamphetamine induced psychosis. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2009**, 33, 895-8	5.5	17
95	Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials. *Molecular Psychiatry*, **2021**, 26, 4146-4157	15.1	17
94	Possible association between ubiquitin-specific peptidase 46 gene and major depressive disorders in the Japanese population. *Journal of Affective Disorders*, **2011**, 133, 150-7	6.6	16
93	Pharmacogenetic study of serotonin 6 receptor gene with antidepressant response in major depressive disorder in the Japanese population. *Human Psychopharmacology*, **2010**, 25, 481-6	2.3	16
92	Glutamate cysteine ligase modifier (GCLM) subunit gene is not associated with methamphetamine-use disorder or schizophrenia in the Japanese population. *Annals of the New York Academy of Sciences*, **2008**, 1139, 63-9	6.5	16
91	Efficacy, Tolerability, and Safety of Blonanserin in Schizophrenia: An Updated and Extended Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Pharmacopsychiatry*, **2019**, 52, 52-62	2	16
90	Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials. *PLoS ONE*, **2014**, 9, e88049	3.7	15
89	COMT Val158Met, but not BDNF Val66Met, is associated with white matter abnormalities of the temporal lobe in patients with first-episode, treatment-naïve major depressive disorder: a diffusion tensor imaging study. *Neuropsychiatric Disease and Treatment*, **2014**, 10, 1183-90	3.1	15
88	P4-193: COMBINATION THERAPY WITH CHOLINESTERASE INHIBITORS AND MEMANTINE FOR ALZHEIMERTS DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS **2014**, 10, P859-P860		14
87	Efficacy and tolerability of clozapine in Japanese patients with treatment-resistant schizophrenia: results from a 12-week, flexible dose study using raters masked to antipsychotic choice. *Asian Journal of Psychiatry*, **2013**, 6, 200-7	6.7	14
86	Voxel-based morphometric brain comparison between healthy subjects and major depressive disorder patients in Japanese with the s/s genotype of 5-HTTLPR. *Scientific Reports*, **2017**, 7, 3931	4.9	14
85	PROKR2 is associated with methamphetamine dependence in the Japanese population. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2010**, 34, 1033-6	5.5	14
84	Alpha4 and beta2 subunits of neuronal nicotinic acetylcholine receptor genes are not associated with methamphetamine-use disorder in the Japanese population. *Annals of the New York Academy of Sciences*, **2008**, 1139, 70-82	6.5	14

83	Relationship between G1287A of the NET Gene Polymorphisms and Brain Volume in Major Depressive Disorder: A Voxel-Based MRI Study. *PLoS ONE*, **2016**, 11, e0150712	3.7	14
82	Add-on fluvoxamine treatment for schizophrenia: an updated meta-analysis of randomized controlled trials. *European Archives of Psychiatry and Clinical Neuroscience*, **2013**, 263, 633-41	5.1	13
81	Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. *CNS Drugs*, **2013**, 27, 731-41	6.7	13
80	Serotonin 6 receptor gene and mood disorders: case-control study and meta-analysis. *Neuroscience Research*, **2010**, 67, 250-5	2.9	13
79	No association between prostate apoptosis response 4 gene (PAWR) in schizophrenia and mood disorders in a Japanese population. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2008**, 147B, 531-4	3.5	13
78	A cross-sectional survey to investigate the prevalence of pain in Japanese patients with major depressive disorder and schizophrenia. *Comprehensive Psychiatry*, **2015**, 59, 91-7	7.3	11
77	Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population. *Drug and Alcohol Dependence*, **2011**, 113, 1-7	4.9	11
76	Translin-associated factor X gene (TSNAX) may be associated with female major depressive disorder in the Japanese population. *NeuroMolecular Medicine*, **2010**, 12, 78-85	4.6	11
75	Effect of Scopolamine Butylbromide on Clozapine-induced Hypersalivation in Schizophrenic Patients: A Case Series. *Clinical Psychopharmacology and Neuroscience*, **2015**, 13, 109-12	3.4	11
74	N-acetylcysteine as an adjunctive treatment for bipolar depression and major depressive disorder: a systematic review and meta-analysis of double-blind, randomized placebo-controlled trials. *Psychopharmacology*, **2020**, 237, 3481-3487	4.7	11
73	Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis. *Psychopharmacology*, **2020**, 237, 1459-1470	4.7	10
72	Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population. *Neuropsychiatric Disease and Treatment*, **2017**, 13, 1281-1302	3.1	10
71	Melatonin receptor agonists-ramelteon and melatonin-for bipolar disorder: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials. *Neuropsychiatric Disease and Treatment*, **2019**, 15, 1479-1486	3.1	10
70	Efficacy and safety of noradrenalin reuptake inhibitor augmentation therapy for schizophrenia: a meta-analysis of double-blind randomized placebo-controlled trials. *Journal of Psychiatric Research*, **2013**, 47, 1557-63	5.2	10
69	Orphan nuclear receptor Rev-erb alpha gene (NR1D1) and fluvoxamine response in major depressive disorder in the Japanese population. *Neuropsychobiology*, **2009**, 59, 234-8	4	10
68	Genetic association analysis of tagging SNPs in alpha4 and beta2 subunits of neuronal nicotinic acetylcholine receptor genes (CHRNA4 and CHRNB2) with schizophrenia in the Japanese population. *Journal of Neural Transmission*, **2008**, 115, 1457-61	4.3	10
67	Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. *Neuropsychiatric Disease and Treatment*, **2016**, 12, 3221-3236	3.1	10
66	Statin add-on therapy in the antipsychotic treatment of schizophrenia: A meta-analysis. *Psychiatry Research*, **2018**, 260, 41-47	9.9	10

65	The relationship between acoustic startle response measures and cognitive functions in Japanese patients with schizophrenia. *NeuroMolecular Medicine*, **2012**, 14, 131-8	4.6	9
64	Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis. *International Journal of Neuropsychopharmacology*, **2018**, 21, 748-757	5.8	9
63	Z-drug for schizophrenia: A systematic review and meta-analysis. *Psychiatry Research*, **2017**, 256, 365-370	9.9	8
62	GTP cyclohydrolase 1 gene haplotypes as predictors of SSRI response in Japanese patients with major depressive disorder. *Journal of Affective Disorders*, **2012**, 142, 315-22	6.6	8
61	Recurrence rates in stable bipolar disorder patients after drug discontinuation drug maintenance: a systematic review and meta-analysis. *Psychological Medicine*, **2021**, 51, 2721-2729	6.9	8
60	Combination Therapy of Serotonin Reuptake Inhibitors and Memantine for Obsessive- Compulsive Disorder: A Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials. *Journal of Alzheimer's Disease*, **2018**, 64, 43-48	4.3	7
59	Aripiprazole for the management of schizophrenia in the Japanese population: a systematic review and meta-analysis of randomized controlled trials. *Neuropsychiatric Disease and Treatment*, **2015**, 11, 419-34	3.1	7
58	Association analysis of functional polymorphism in estrogen receptor alpha gene with schizophrenia and mood disorders in the Japanese population. *Psychiatric Genetics*, **2009**, 19, 217-8	2.9	7
57	A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders. *Neuropsychiatric Disease and Treatment*, **2016**, 12, 3041-3049	3.1	7
56	Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials with an enrichment design. *Neuropsychopharmacology Reports*, **2019**, 39, 241-246	2.2	6
55	Serum Brain-Derived Neurotrophic Factor, and Plasma Catecholamine Metabolites in People with Major Depression: Preliminary Cross-Sectional Study. *Frontiers in Psychiatry*, **2018**, 9, 52	5	6
54	Serotonin 6 receptor gene and schizophrenia: case-control study and meta-analysis. *Human Psychopharmacology*, **2012**, 27, 63-9	2.3	6
53	No significant association between SIRT1 gene and methamphetamine-induced psychosis in the Japanese population. *Human Psychopharmacology*, **2011**, 26, 445-50	2.3	6
52	Effect of aripiprazole, risperidone, and olanzapine on the acoustic startle response in Japanese chronic schizophrenia. *Psychopharmacology*, **2010**, 209, 185-90	4.7	6
51	Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials. *Neuropsychiatric Disease and Treatment*, **2018**, 14, 2519-2530	3.1	6
50	COMT polymorphism regulates the hippocampal subfield volumes in first-episode, drug-naive patients with major depressive disorder. *Neuropsychiatric Disease and Treatment*, **2019**, 15, 1537-1545	3.1	5
49	Prostate apoptosis response 4 gene is not associated with methamphetamine-use disorder in the Japanese population. *Annals of the New York Academy of Sciences*, **2008**, 1139, 83-8	6.5	5
48	Efficacy and tolerability of Z-drug adjunction to antidepressant treatment for major depressive disorder: a systematic review and meta-analysis of randomized controlled trials. *European Archives of Psychiatry and Clinical Neuroscience*, **2017**, 267, 149-161	5.1	4

47	Early prediction of blonanserin response in Japanese patients with schizophrenia. *Neuropsychiatric Disease and Treatment*, **2014**, 10, 1861-6	3.1	4
46	Efficacy and tolerability of high dose olanzapine in Japanese patients with treatment-resistant schizophrenia. *Asian Journal of Psychiatry*, **2013**, 6, 86-7	6.7	4
45	Relationship between nicotine dependence and the endophenotype-related trait of cognitive function but not acoustic startle reponses in Japanese patients with schizophrenia. *Human Psychopharmacology*, **2013**, 28, 220-9	2.3	4
44	Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder. *Neuropsychiatric Disease and Treatment*, **2013**, 9, 781-6	3.1	4
43	Association Analysis of Nuclear Receptor Rev-erb Alpha Gene (NR1D1) and Japanese Methamphetamine Dependence. *Current Neuropharmacology*, **2011**, 9, 129-32	7.6	4
42	Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta-analysis of phase 3 trials in Japan. *Neuropsychopharmacology Reports*, **2020**, 40, 314-322	2.2	4
41	Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan. *Journal of Psychiatric Research*, **2021**, 138, 444-452	5.2	4
40	Plasma levels of IL-6 in patients with untreated major depressive disorder: comparison with catecholamine metabolites. *Neuropsychiatric Disease and Treatment*, **2019**, 15, 2655-2661	3.1	3
39	Comparison of quetiapine immediate- and extended-release formulations for bipolar depression: A systematic review and network meta-analysis of double-blind, randomized placebo-controlled trials. *Journal of Psychiatric Research*, **2019**, 115, 121-128	5.2	3
38	Suvorexant for insomnia in patients with psychiatric disorder: A 1-week, open-label study. *Neuropsychopharmacology Reports*, **2019**, 39, 252-255	2.2	3
37	Lack of association between translin-associated factor X gene (TSNAX) and methamphetamine dependence in the Japanese population. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2011**, 35, 1618-22	5.5	3
36	Memantine treatment for Japanese patients with moderate to severe Alzheimer's disease: a meta-analysis of double-blind, randomized, placebo-controlled trials. *Neuropsychiatric Disease and Treatment*, **2018**, 14, 2915-2922	3.1	3
35	Blonanserin patch vs. Other Antipsychotics for Acute Schizophrenia: A Systematic Review of Double-blind, Randomized, Placebo-controlled, Phase 3 Trials in Japan. *Pharmacopsychiatry*, **2020**, 53, 122-132	2	2
34	Quetiapine extended-release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis. *Neuropsychopharmacology Reports*, **2019**, 39, 256-259	2.2	2
33	A single-nucleotide polymorphism influences brain morphology in drug-naïve patients with major depressive disorder. *Neuropsychiatric Disease and Treatment*, **2019**, 15, 2425-2432	3.1	2
32	The position of blonanserin as a treatment for schizophrenia. *Asia-Pacific Psychiatry*, **2014**, 6, 462	3.2	2
31	Lack of association between prokineticin 2 gene and Japanese methamphetamine dependence. *Current Neuropharmacology*, **2011**, 9, 133-6	7.6	2
30	Genetic Association Analysis of NOS1 and Methamphetamine-Induced Psychosis Among Japanese. *Current Neuropharmacology*, **2011**, 9, 155-9	7.6	2

29	Lack of association between MAGEL2 and schizophrenia and mood disorders in the Japanese population. *NeuroMolecular Medicine*, **2010**, 12, 285-91	4.6	2
28	Melatonin receptor agonists for bipolar mania: A systematic review and meta-analyses of double-blind randomized placebo-controlled trials. *Bipolar Disorders*, **2021**, 23, 301-302	3.8	2
27	Body composition in Japanese patients with psychiatric disorders: A cross-sectional study. *Neuropsychopharmacology Reports*, **2021**, 41, 117-121	2.2	2
26	Effects of a conventional mood stabilizer alone or in combination with second-generation antipsychotics on recurrence rate and discontinuation rate in bipolar I disorder in the maintenance phase: A systematic review and meta-analysis of randomized, placebo-controlled trials. *Bipolar Disorders*, **2021**,	3.8	2
25	Outcomes of patients with schizophrenia who discontinued long-acting injectable antipsychotic therapy due to adverse events: A chart review. *Neuropsychopharmacology Reports*, **2021**, 41, 422-425	2.2	2
24	Evidence-based insomnia treatment strategy using novel orexin antagonists: A review. *Neuropsychopharmacology Reports*, **2021**,	2.2	2
23	No significant association between brain-derived neurotrophic factor gene rs6265 and cognitive function in Japanese patients with schizophrenia. *Psychiatry Research*, **2014**, 215, 803-5	9.9	1
22	Further evidence of an association between a genetic variant in BMP7 and treatment response to SSRIs in major depressive disorder. *Journal of Human Genetics*, **2013**, 58, 568-9	4.3	1
21	No Association Between GRM3 and Japanese Methamphetamine-Induced Psychosis. *Current Neuropharmacology*, **2011**, 9, 160-2	7.6	1
20	Early improvement as a predictor of response to blonanserin transdermal patch in patients with schizophrenia.. *Schizophrenia Research*, **2022**, 240, 231-232	3.6	1
19	Association of Serum Kynurenine Levels and Neural Networks in Patients with First-Episode, Drug-Naïve Major Depression: A Source-Based Morphometry Study. *Neuropsychiatric Disease and Treatment*, **2020**, 16, 2569-2577	3.1	1
18	Factors associated with discontinuation in the drug and placebo groups of trials of second generation antipsychotics for acute schizophrenia: A meta-regression analysis: Discontinuation in antipsychotic trials. *Journal of Psychiatric Research*, **2020**, 130, 240-246	5.2	1
17	Lurasidone, olanzapine, and quetiapine extended-release for bipolar depression: A systematic review and network meta-analysis of phase 3 trials in Japan. *Neuropsychopharmacology Reports*, **2020**, 40, 417-422	2.2	1
16	Duration of long-acting injectable antipsychotic treatment and reasons for its discontinuation: A chart review of patients with schizophrenia. *Psychiatry and Clinical Neurosciences*, **2021**, 75, 240	6.2	1
15	Association between discontinuation due to withdrawal of consent and use of long-acting injectable antipsychotics: A meta-analysis of randomized trials for schizophrenia. *Journal of Psychiatric Research*, **2021**, 132, 144-150	5.2	1
14	Recurrence Rates in Stable Bipolar Disorder Patients after Drug Discontinuation versus Drug Maintenance: A Systematic Review and Meta-analysis - Corrigendum. *Psychological Medicine*, **2021**, 51, 2730	6.9	1
13	Clinical Investigation of Accumulation Process of 99mTc-HMDP and -MDP in Bone. *Radioisotopes*, **2000**, 49, 292-297	0.1	0
12	Omega-3 fatty acids for treating residual depressive symptoms in adult patients with bipolar disorder: A systematic review and meta-analysis of double-blind randomized, placebo-controlled trials. *Bipolar Disorders*, **2021**, 23, 730-731	3.8	0

11	Early Improvement as a Predictor of Later Response to Lurasidone in Schizophrenia from Japan Trials: A Diagnostic Test.. *Psychiatry and Clinical Neurosciences*, **2022**,	6.2	0
10	Short-term adjunct of topiramate to antipsychotics in schizophrenia improves the psychopathology and has weight maintenance. *Evidence-Based Mental Health*, **2017**, 20, 61	11.1	
9	Vortioxetine vs placebo in major depressive disorder: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled, phase 3 trials in Japan. *Psychiatry and Clinical Neurosciences*, **2020**, 74, 330-332	6.2	
8	Response to the letter from Dr. Kim and colleagues. *Psychiatry Research*, **2018**, 263, 291-292	9.9	
7	Lack of improvement at week 2 predicts later antipsychotic non-response in people with acute exacerbations of schizophrenia or schizophrenia-like psychosis. *Evidence-Based Mental Health*, **2016** , 19, 61	11.1	
6	Response to the letter from Dr. Veerman and colleagues. *Psychopharmacology*, **2017**, 234, 3537-3538	4.7	
5	Observations on the results of a systematic review and network meta-analysis of double-blind randomized, placebo-controlled trials to examine early onset of response to pharmacological intervention for bipolar depression. *Bipolar Disorders*, **2021**,	3.8	
4	Routine use of antipsychotics to prevent or treat delirium is not recommended. *Evidence-Based Mental Health*, **2016**, 19, 123	11.1	
3	Response to the Letter from Dr. Jacob Peedicayil. *Psychopharmacology*, **2019**, 236, 1403-1404	4.7	
2	Differences in the incidence of lurasidone adverse events between depressive disorders and schizophrenia in double-blind, randomized, placebo-controlled trials: a meta-analysis. *Psychopharmacology*, **2021**, 238, 3585-3593	4.7	
1	Volume of Amygdala Subregions and Plasma Levels of Brain-Derived Neurotrophic Factor and Cortisol in Patients with s/s Genotype of Serotonin Transporter Gene Polymorphism of First-Episode and Drug-Naive Major Depressive Disorder: An Exploratory Study.. *Neurology International*, **2022**, 14, 378-390	1.2	